Zentalis Pharmaceuticals Inc
For the period ended Jun 30, 2024. Filed Aug 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 9, 2024
ZNTL$1.80+3.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Six Months EndedJune 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating Activities: | ||
| Consolidated net loss | $(78,237) | $(175,826) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 651 | 704 |
| Operating lease right-of-use asset and fixed asset impairment | — | 4,953 |
| Noncash consideration portion of Zentera in-process research and development | — | 15,045 |
| Loss on equity method investment | — | 16,014 |
| Share-based compensation | 25,544 | 27,075 |
| Loss on disposal of equipment | (13) | (4) |
| Non-cash impact of license revenue | (25,560) | — |
| Non-cash recognized mark-to-market of equity securities | (2,253) | — |
| Accretion of discounts on marketable securities, net | (4,960) | (6,483) |
| Deferred income taxes | — | (853) |
| Deconsolidation of Kalyra | (79) | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 550 | (3,922) |
| Accounts payable and accrued liabilities | (3,452) | (5,805) |
| Operating lease right-of-use assets and liabilities, net | 696 | 544 |
| Net cash used in operating activities | (87,113) | (128,558) |
| Investing Activities: | ||
| Purchases of marketable securities | (29,509) | (189,085) |
| Proceeds from maturities of marketable securities | 125,700 | 304,457 |
| Proceeds from sale of property and equipment | 65 | — |
| Purchases of property and equipment | (221) | (319) |
| Net cash provided by investing activities | 96,035 | 115,053 |
| Financing Activities: | ||
| Proceeds from issuance of common stock, net | — | 235,680 |
| Proceeds from issuance of common stock under equity incentive plans | 257 | 1,314 |
| Net-settlement of restricted stock unit vesting | (241) | — |
| Net cash provided by financing activities | 16 | 236,994 |
| Net increase in cash, cash equivalents and restricted cash | 8,938 | 223,489 |
| Cash, cash equivalents and restricted cash at beginning of period | 30,719 | 45,696 |
| Cash, cash equivalents and restricted cash at end of period | $39,657 | $269,185 |
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the Consolidated Statements of Cash Flows for the periods presented:
| June 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash and cash equivalents | $36,976 | $266,558 |
| Restricted cash | 2,681 | 2,627 |
| Total cash, cash equivalents and restricted cash reported in the Condensed Consolidated Statement of Cash Flows | $39,657 | $269,185 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.